|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zakaria N, Satar NA, Abu Halim NH, Ngalim
SH, Yusoff NM, Lin J and Yahaya BH: Targeting lung cancer stem
cells: Research and clinical impacts. Front Oncol. 7:802017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Z, Zhou Y, Qian H, Shao G, Lu X,
Chen Q, Sun X, Chen D, Yin R, Zhu H, et al: Stemness and inducing
differentiation of small cell lung cancer NCI-H446 cells. Cell
Death Dis. 4:e6332013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rahman M, Deleyrolle L, Vedam-Mai V, Azari
H, Abd-El-Barr M and Reynolds BA: The cancer stem cell hypothesis:
Failures and pitfalls. Neurosurgery. 68:531–545. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tysnes BB and Bjerkvig R: Cancer
initiation and progression: Involvement of stem cells and the
microenvironment. Biochim Biophys Acta. 1775:283–297.
2007.PubMed/NCBI
|
|
6
|
Qiu X, Wang Z, Li Y, Miao Y, Ren Y and
Luan Y: Characterization of sphere-forming cells with stem-like
properties from the small cell lung cancer cell line H446. Cancer
Lett. 323:161–170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiao J, Mu JS, Liu TR and Xu HN: Dig the
root of cancer: Targeting cancer stem cells therapy. J Med Discov.
2:1–6. 2017.
|
|
8
|
Sato A, Sunayama J, Okada M, Watanabe E,
Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T, et al:
Glioma-initiating cell elimination by metformin activation of FOXO3
via AMPK. Stem Cells Transl Med. 1:811–824. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yung MM, Chan DW, Liu VW, Yao KM and Ngan
HY: Activation of AMPK inhibits cervical cancer cell growth through
AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 13:3272013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Queiroz EA, Puukila S, Eichler R, Sampaio
SC, Forsyth HL, Lees SJ, Barbosa AM, Dekker RF, Fortes ZB and
Khaper N: Metformin induces apoptosis and cell cycle arrest
mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast
cancer cells. PLoS One. 9:e982072014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He L, Yang X, Cao X, Liu F, Quan M and Cao
J: Casticin induces growth suppression and cell cycle arrest
through activation of FOXO3a in hepatocellular carcinoma. Oncol
Rep. 29:103–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu LP, Cao XC, Liu F, Quan MF, Sheng XF
and Ren KQ: Casticin induces breast cancer cell apoptosis by
inhibiting the expression of forkhead box protein M1. Oncol Lett.
7:1711–1717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang L, Cao XC, Cao JG, Liu F, Quan MF,
Sheng XF and Ren KQ: Casticin induces ovarian cancer cell apoptosis
by repressing FoxM1 through the activation of FOXO3a. Oncol Lett.
5:1605–1610. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shrestha A, Nepal S, Kim MJ, Chang JH, Kim
SH, Jeong GS, Jeong CH, Park GH, Jung S, Lim J, et al: Critical
role of AMPK/FoxO3A axis in globular adiponectin-induced cell cycle
arrest and apoptosis in cancer cells. J Cell Physiol. 231:357–369.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Y, Sun Y, Ding Y, Wang X, Zhou Y, Li
W, Huang S, Li Z, Kong L, Guo Q, et al: GL-V9, a new synthetic
flavonoid derivative, ameliorates DSS-induced colitis against
oxidative stress by up-regulating Trx-1 expression via activation
of AMPK/FOXO3a pathway. Oncotarget. 6:26291–26307. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng F, Wu J, Zhao S, Luo Q, Tang Q, Yang
L, Li L, Wu W and Hann SS: Baicalein increases the expression and
reciprocal interplay of RUNX3 and FOXO3a through crosstalk of
AMPKalpha and MEK/ERK1/2 signaling pathways in human non-small cell
lung cancer cells. J Exp Clin Cancer Res. 34:412015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu F, Cao X, Liu Z, Guo H, Ren K, Quan M,
Zhou Y, Xiang H and Cao J: Casticin suppresses self-renewal and
invasion of lung cancer stem-like cells from A549 cells through
down-regulation of pAkt. Acta Biochim Biophys Sin. 46:15–21. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bonini MG and Gantner BN: The multifaceted
activities of AMPK in tumor progression-why the ‘one size fits all’
definition does not fit at all? IUBMB Life. 65:889–896. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen D, Cao J, Tian L, Liu F and Sheng X:
Induction of apoptosis by casticin in cervical cancer cells through
reactive oxygen species-mediated mitochondrial signaling pathways.
Oncol Rep. 26:1287–1294. 2011.PubMed/NCBI
|
|
20
|
Zhou Y, Peng Y, Mao QQ, Li X, Chen MW, Su
J, Tian L, Mao NQ, Long LZ, Quan MF, et al: Casticin induces
caspase-mediated apoptosis via activation of mitochondrial pathway
and upregulation of DR5 in human lung cancer cells. Asian Pac J
Trop Med. 6:372–378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
He M, Cao XC, He GC, Sheng XF, Ai XH and
Wu YH: Casticin inhibits epithelial-mesenchymal transition of liver
cancer stem cells of the SMMC-7721 cell line through downregulating
Twist. Oncol Lett. 7:1625–1631. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He G, Cao X, He M, Sheng X, Wu Y and Ai X:
Casticin inhibits self-renewal of liver cancer stem cells from the
MHCC97 cell line. Oncol Lett. 7:2023–2028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chou CC, Lee KH, Lai IL, Wang D, Mo X,
Kulp SK, Shapiro CL and Chen CS: AMPK reverses the mesenchymal
phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a
signaling axis. Cancer Res. 74:4783–4795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo Q, Liu Z, Jiang L, Liu M, Ma J, Yang
C, Han L, Nan K and Liang X: Metformin inhibits growth of human
non-small cell lung cancer cells via liver kinase B-1-independent
activation of adenosine monophosphate-activated protein kinase. Mol
Med Rep. 13:2590–2596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gutova M, Najbauer J, Gevorgyan A, Metz
MZ, Weng Y, Shih CC and Aboody KS: Identification of uPAR-positive
chemoresistant cells in small cell lung cancer. PLoS One.
2:e2432007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
LeBeau AM, Duriseti S, Murphy ST, Pepin F,
Hann B, Gray JW, VanBrocklin HF and Craik CS: Targeting uPAR with
antagonistic recombinant human antibodies in aggressive breast
cancer. Cancer Res. 73:2070–2081. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma YY and Tao HQ: Role of urokinase
plasminogen activator receptor in gastric cancer: A potential
therapeutic target. Cancer Biother Radiopharm. 27:285–290. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Codony-Servat J, Verlicchi A and Rosell R:
Cancer stem cells in small cell lung cancer. Transl Lung Cancer
Res. 5:16–25. 2016.PubMed/NCBI
|
|
30
|
Chiacchiera F, Matrone A, Ferrari E,
Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L,
Moschetta A and Simone C: p38alpha blockade inhibits colorectal
cancer growth in vivo by inducing a switch from HIF1alpha- to
FoxO-dependent transcription. Cell Death Differ. 16:1203–1214.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gopinath S, Malla RR, Gondi CS, Alapati K,
Fassett D, Klopfenstein JD, Dinh DH, Gujrati M and Rao JS:
Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma
via FOXO3a mediated p27 upregulation. PLoS One. 5:e116682010.
View Article : Google Scholar : PubMed/NCBI
|
